A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype
Latest Information Update: 02 Jul 2026
At a glance
- Drugs Dupilumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms LIBERTY-UC SUCCEED
- Sponsors Sanofi
Most Recent Events
- 23 Jun 2026 Planned End Date changed from 19 Feb 2027 to 22 Feb 2027.
- 15 Dec 2025 Planned End Date changed from 24 Mar 2027 to 19 Feb 2027.
- 15 Dec 2025 Planned primary completion date changed from 17 Jun 2026 to 15 May 2026.